OverviewChartNews
Derivatives
TraderScreen

Blueprint Medicines Corp/  US09627Y1091  /

IEX
2024-09-19  9:59:59 PM Chg. +1.66 Volume Bid- Ask- High Low
90.96USD +1.86% 47,385
Turnover: 4.36 mill.		 -Bid Size: - -Ask Size: - 93.62 90.67
GlobeNewswire 08-05 Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
GlobeNewswire 05-27 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medi...
GlobeNewswire 05-23 BPMC INVESTOR ALERT: Andrews & Springer LLC Investigates Blueprint Medicines Corporation
GlobeNewswire 05-20 BPMC Alert: The Law Firm of Andrews & Springer LLC Is Investigating Blueprint Medicines Corporation ...
GlobeNewswire 05-17 Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and ...
GlobeNewswire 05-14 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire 05-09 Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
GlobeNewswire 05-02 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...
GlobeNewswire 04-23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 03-11 FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
GlobeNewswire 03-06 Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
GlobeNewswire 02-28 Recludix Pharma to Participate in Two Investor Conferences in March
GlobeNewswire 02-06 Recludix Pharma to Present at Two Investor Conferences in February
GlobeNewswire 01-17 Day One Announces Two New Appointments to Board of Directors
GlobeNewswire 2023-11-15 T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to tr...
GlobeNewswire 2023-11-09 Recludix Pharma to Present at Two Investor Conferences in November
GlobeNewswire 2023-10-31 Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile...
GlobeNewswire 2023-10-17 Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conf...
GlobeNewswire 2023-08-30 Recludix Pharma to Participate in Multiple Investor Conferences in September
GlobeNewswire 2023-08-29 Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whol...
GlobeNewswire 2022-03-10 Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update...
GlobeNewswire 2022-03-01 Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
GlobeNewswire 2022-01-18 Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
GlobeNewswire 2022-01-10 Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Caus...
GlobeNewswire 2022-01-06 Recludix Pharma Announces Scientific Advisory Board